

M Cecilia Bahit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11050560/publications.pdf>

Version: 2024-02-01

22
papers

9,679
citations

567281

15
h-index

713466

21
g-index

22
all docs

22
docs citations

22
times ranked

9456
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 227-235.	3.0	6
2	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	1.6	118
3	Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke. <i>JAMA Cardiology</i> , 2022, 7, 682.	6.1	3
4	Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. <i>Open Heart</i> , 2021, 8, e001471.	2.3	7
5	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 1215-1223.	1.6	9
6	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e023143.	3.7	0
7	Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2020, 302, 53-58.	1.7	5
8	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 380, 1509-1524.	27.0	833
9	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. <i>Circulation</i> , 2019, 139, 2292-2300.	1.6	78
10	Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2018, 197, 133-141.	2.7	17
11	Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. <i>Heart</i> , 2017, 103, 623-628.	2.9	54
12	First-Ever Stroke and Transient Ischemic Attack Incidence and 30-Day Case-Fatality Rates in a Population-Based Study in Argentina. <i>Stroke</i> , 2016, 47, 1640-1642.	2.0	42
13	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016, 175, 175-183.	2.7	16
14	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 86-94.	3.0	59
15	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	68
16	Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Circulation</i> , 2015, 132, 624-632.	1.6	203
17	Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2015, 169, 25-30.	2.7	61
18	Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>American Heart Journal</i> , 2014, 168, 303-309.	2.7	128

#	ARTICLE	IF	CITATIONS
19	Program for the Epidemiological Evaluation of Stroke in Tandil, Argentina (PREVISTA) Study: Rationale and Design. <i>International Journal of Stroke</i> , 2013, 8, 591-597.	5.9	8
20	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 1749-1758.	13.7	175
21	Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. <i>Lancet Neurology</i> , The, 2012, 11, 503-511.	10.2	252
22	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	27.0	7,537